51. Scleroderma Clinical trials / Disease details

Clinical trials : 523 / Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03593902 (ClinicalTrials.gov)	May 17, 2018	28/6/2018	Cardiac Safe Transplants for Systemic Sclerosis	Autologous Hematopoietic Stem Cell Transplant for Patients With Systemic Sclerosis and Cardiac Dysfunction	Systemic Sclerosis;Scleroderma	Drug: Rituximab;Drug: Fludarabine;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells	Northwestern University	NULL	Terminated	18 Years	65 Years	All	9	Phase 2/Phase 3	United States
2	NCT01445821 (ClinicalTrials.gov)	September 15, 2011	29/9/2011	Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial	Randomized Study of Different Non-myeloablative Conditioning Regimens With Hematopoietic Stem Cell Support in Patients With Scleroderma (Autologous Systemic Sclerosis Immune Suppression Trial - II ASSIST-IIb)	Scleroderma, Systemic	Biological: Peripheral Blood Stem Cells;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: Filgrastim;Drug: Fludarabine	Northwestern University	NULL	Terminated	17 Years	60 Years	All	44	Phase 3	United States
3	NCT00278525 (ClinicalTrials.gov)	September 2005	15/1/2006	Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma	Trial of High Dose Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG) With Hematopoietic Stem Cell Support in Patients With Systemic Scleroderma: A Randomized Trial	SYSTEMIC SCLERODERMA	Drug: standard of care;Procedure: stem cell transplantation	Northwestern University	NULL	Completed	N/A	60 Years	All	19	Phase 2	United States